EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC 3.0

Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients

Ruanjuan Zhan iD, Yuxin Shen, Haoxin Fu, Hualu Wu, Xiaohai Chen iD, Yige Yu, Ren-Ai Xu

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s509176 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Ruanjuan Zhan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Purines, Tandem Mass Spectrometry, Drug Monitoring, Azetidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Baricitinib is widely used as a selective Janus kinase (JAK) inhibitor for the treatment of immune-mediated inflammatory diseases in clinic. It is now successfully applied in reducing inflammation and suppressing COVID-19-associated immune dysregulation. As knowledge of the appropriate plasma level of baricitinib in COVID-19 patients is deficient, the measurement of the level of baricitinib in plasma during treatment is necessary and important.

Purpose

The aim of this study was to establish a bioanalytical method to detect the concentration of baricitinib in COVID-19 patients' plasma by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).

Methods

The preparation process of the injected sample was to spike 100 μL of plasma and 10 μL of internal standard (IS, upadacitinib) working solution, then add 1:3 of acetonitrile to obtain the supernatant. The intra-day and inter-day precision and accuracy, matrix effect, recovery, and stability of the established methodology were all required.

Results

The method was established to determine the plasma levels in 22 COVID-19 patients. After taking 2 mg/day or 4 mg/day of baricitinib, the mean plasma concentrations of the patients were 15.36 ng/mL and 12.64 ng/mL, respectively.

Conclusion

This novel UPLC-MS/MS method enables rapid and accurate determination of baricitinib concentrations in human plasma, which is suitable for the therapeutic drug monitoring (TDM) of baricitinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PurinesTandem Mass SpectrometryDrug MonitoringAzetidinesSulfonamidesCOVID-19 Drug TreatmentPyrazolesHumansChromatography, High Pressure LiquidCOVID-19MaleMiddle AgedFemaleReproducibility of ResultsSARS-CoV-2Liquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

COVID-19UPLC-MS/MSbaricitinibdrug monitoring

Substanzen

baricitinibPurinesAzetidinesSulfonamidesPyrazoles

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.

ORCID-Profile: Ruanjuan Zhan, Xiaohai Chen

Zitieren

APA

Zhan, R., Shen, Y., Fu, H., Wu, H., Chen, X., Yu, Y., & Xu, R. A. (2025). Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s509176

Vancouver

Zhan R, Shen Y, Fu H, Wu H, Chen X, Yu Y, et al. Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s509176

BibTeX
@article{Zhan2025,
  author = {Zhan, Ruanjuan and Shen, Yuxin and Fu, Haoxin and Wu, Hualu and Chen, Xiaohai and Yu, Yige and Xu, Ren-Ai},
  title = {Development and Validation of a UPLC-MS/MS Detection Method of Baricitinib for Therapeutic Drug Monitoring in COVID-19 Patients},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s509176}
}
Kostenlos starten →